SCHEMBL3415410

SCHEMBL3415410

CCOc1ncc(-c2cccc(C(=O)O)c2)cc1CNC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 1/20 0.50
SCN10A Q9Y5Y9 1/20 0.50
PPARG P37231 3/20 0.46
PPARA Q07869 3/20 0.46
TP53 P04637 2/20 0.46
ACLY P53396 1/20 0.45
PPARD Q03181 2/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 1/20 0.44
MAP4K4 O95819 1/20 0.42
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3415713 0.91 PPARD (0.53) SCN2ASCN10APPARGPPARAACLY
SCHEMBL3415544 0.90 PPARD (0.47) SCN2ASCN10APPARGPPARATP53
SCHEMBL3416566 0.89 NR1H4 (0.44) SCN2ASCN10APPARGPPARATP53
SCHEMBL3418619 0.88 SCN2A (0.45) SCN2ASCN10APPARGTP53PPARD
SCHEMBL13460851 0.86 SCN2A (0.45) SCN2ASCN10APPARGTP53HPGD
SCHEMBL3418691 0.86 PPARD (0.56) PPARGPPARATP53ACLYPPARD
SCHEMBL3414951 0.81 PPARA (0.58) SCN2ASCN10APPARGPPARAACLY
SCHEMBL3418870 0.81 PPARD (0.69) PPARGPPARAPPARDEPHX2
SCHEMBL3417151 0.81 PPARD (0.61) PPARGPPARATP53ACLYPPARD
SCHEMBL3414230 0.80 PPARA (0.63) PPARGPPARATP53ACLYPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687664-B2 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-30 US disclosed
US-7687664-B2 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-30 US disclosed
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-10-28 US disclosed
EP-1394147-A1 CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME Eisai Co., Ltd. (JP) 2004-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same GPR119, NR3C1, INSR SCN2A 191/4885SCN10A 471/4885PPARG 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.